Clinical Trial Update: Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer [Phase 2]

View source ↗

Summary

This Phase II trial compared preoperative FOLFIRINOX versus gemcitabine/nab-paclitaxel in resectable pancreatic cancer; the study was terminated and results wer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer
• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• FLUOROURACIL (Fluorouracil)
• FOLFIRINOX
• Gemcitabine (Gemcitabine)
• Irinotecan (Irinotecan)
• Leucovorin (folinic acid)
• Nab-paclitaxel (paclitaxel protein-bound)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Massachusetts General Hospital | Conditions: Resectable Pancreatic Cancer, Pancreatic Ductal Carcinoma | Phase 2 | Status: TERMINATED | Results posted: 2017-05-16